ELLANSÉ

ELLANSÉ™ M

Manufacturer: Sinclair Active Substance(s): POLYCAPROLACTONE MICROSPHERES, CARBOXYMETHYLCELLULOSE…

ADD TO CART VIEW PRODUCT

-+

$280.00

ELLANSÉ™ S

Manufacturer: Sinclair Active Substance(s): POLYCAPROLACTONE MICROSPHERES, CARBOXYMETHYLCELLULOSE…

ADD TO CART VIEW PRODUCT

-+

$349.00

About Ellansé — A Dual-Action Collagen Stimulator Filler

Ellansé bridges the gap between traditional dermal fillers and pure collagen stimulators [1][2]. Its carboxymethylcellulose (CMC) carrier provides immediate visible volumisation at the time of injection, while PCL microspheres stimulate fibroblasts to produce new collagen progressively over the months that follow [1][2]. This dual-action mechanism means patients see aesthetic results on the day of treatment, with continued structural improvement as neocollagenesis advances and the CMC carrier is gradually resorbed [1][2].

This combination addresses both the immediate aesthetic expectations typical of filler patients and the longer-term structural support that collagen stimulators provide — from a single product and a single injection session [1][2].

The Ellansé Manufacturer — Sinclair Pharma

Sinclair Pharma is an international specialty aesthetic medicine company and the manufacturer of Ellansé, alongside other professional injectable products including Perfectha [4]. CE-marked in the EU and distributed in multiple international markets [1][4], Sinclair Pharma’s portfolio reflects a focus on clinical evidence and regulatory compliance. Practitioners using Ellansé have access to peer-reviewed data supporting the product’s mechanism, safety profile, and efficacy across facial aesthetic indications [1][2][3].

The Science Behind Ellansé — PCL Microspheres and Collagen Induction

Ellansé is a non-pyrogenic, biocompatible, bioresorbable synthetic filler composed of polycaprolactone (PCL) microspheres suspended in a carboxymethylcellulose (CMC) carrier gel [1][2][4]. PCL is a synthetic biocompatible polymer with an established history in medical applications, including absorbable sutures [2]. The CMC carrier is cellulose-derived, providing the viscosity required for injection while acting as the immediate volumizing component [1][4].

In the immediate phase following injection, the CMC carrier delivers visible correction [1][2]. Over subsequent weeks and months, the body gradually resorbs the carrier while PCL microspheres stimulate dermal fibroblasts to synthesize new collagen in the treated area [1][2]. Collagen formation builds progressively, with results continuing to develop and improve as PCL degrades through natural biological processes [2][3].

On the question of migration: technique and injection depth are critical to minimizing migration and nodule risk [1]. When Ellansé is placed in the recommended injection plane per the product IFU, the risk of migration is reduced [1][4]. Placement outside the recommended depth increases the risk of migration and nodule formation; strict adherence to injection plane guidance is essential [1][4].

Because Ellansé is not a hyaluronic acid filler, hyaluronidase does not dissolve it [4][5]. The enzyme used to reverse HA fillers has no effect on PCL or CMC components. This must be communicated clearly during patient consultation and documented in the informed consent process before treatment [4].

Ellansé Product Range — Choosing the Right Duration

The four Ellansé variants share the same PCL and CMC technology but differ in PCL concentration and polymer chain length, which determines the rate of degradation and overall duration of aesthetic results [1]. Each variant carries the same safety profile and collagen-stimulating mechanism; longevity is the sole variable [1].

• Ellansé-S offers approximately one year of duration, suited to patients new to collagen-stimulating fillers or those preferring a shorter initial commitment.
• Ellansé-M provides approximately two years, offering a versatile intermediate option.
• Ellansé-L delivers approximately three years of results, suited to patients and practitioners seeking sustained volumisation with less frequent follow-up.
• Ellansé-E is the longest-duration variant at approximately four years, designed for those seeking extended intervals between treatment sessions [1].

Deeper anatomical structures typically support longer-duration variants, while higher-mobility or thinner areas may be better suited to shorter durations [1]. This range of options gives practitioners a meaningful clinical tool for aligning treatment plans with individual patient profiles — an advantage not offered by single-duration biostimulators [1].

Treatment Areas and Clinical Indications

Ellansé is used for facial volume restoration and contouring, with documented treatment in areas such as the midface, lower face, nasolabial folds, jawline, and temples [1][3]. Injection is performed in the recommended plane per the product IFU [1][4]. Clinical use is focused on the face; off-label use in other areas may be referenced in some clinical settings, though such applications remain outside the formal regulatory indication [4].

Professionals can buy Ellansé dermal filler for patients looking for facial aesthetic procedures that can address age-related volume loss, skin laxity, or loss of structural support [1][2]. Technique and injection depth are critical to safe and effective treatment; placement outside the recommended injection plane increases the risk of nodule formation and is not consistent with the product’s instructions for use [1][4].

Injection Protocol and Administration

Ellansé is administered via injection in the recommended plane — deep dermis to subcutaneous tissue per the product IFU — using bolus placement or linear threading, performed by a licensed aesthetic practitioner [1][4]. Intravascular placement carries a risk of serious complications including tissue necrosis and should be avoided through careful technique and thorough anatomical knowledge [4][5].

Ellansé is supplied as a prefilled syringe. Volume and placement are determined by the treatment zone and the practitioner’s clinical judgment, in accordance with the product IFU [1][4]. Post-procedure care should follow the product IFU and clinician guidance [4].

How long Ellansé remains in the skin depends on the variant chosen: Ellansé-S approximately one year, Ellansé-M approximately two years, Ellansé-L approximately three years, and Ellansé-E approximately four years [1].

Why Practitioners Choose Ellansé

Two characteristics distinguish Ellansé from competing biostimulator and filler options.

1. The four-duration S/M/L/E range allows practitioners to tailor product longevity to individual patient anatomy, treatment zones, and maintenance preferences [1]. Most competing collagen stimulators are available in a single duration, which limits the practitioner’s ability to individualize treatment plans. Ellansé’s variant structure supports patient-specific planning from the initial consultation.
2. The dual-action mechanism delivers immediate CMC-based volumisation alongside progressive PCL-driven collagen induction [1][2]. Traditional HA fillers provide static volumisation that diminishes as the product degrades; single-action biostimulators such as Sculptra® provide no immediate correction and require patient tolerance of a delayed-result timeline. Ellansé addresses both of these clinical considerations within a single treatment [1][2].

Regulatory Status and Availability

Ellansé is CE-marked in the EU and distributed in multiple international markets, manufactured in compliance with applicable medical device regulations [1][4]. CE marking confirms that the product meets the essential health and safety requirements for medical devices within the EU [4].

For US availability: Ellansé is not FDA-approved or cleared for the US market [5]. It is not marketed as an FDA-approved dermal filler in the US [5]. Practitioners outside EU and CE-recognized markets should verify local regulatory status before ordering or administering [4].

Ellansé vs Competing Collagen Stimulators and Fillers

Ellansé vs Sculptra

Sculptra® (poly-L-lactic acid, PLLA) is a collagen biostimulator that works gradually over two to three months, with no immediate volumisation at the time of injection. Ellansé provides immediate CMC-based correction alongside PCL-driven collagen induction, making same-day visible results part of the treatment outcome [1][2]. Practitioners stocking both approaches can buy Sculptra® at Medica Depot — the choice between them reflects whether immediate correction or a purely gradual biostimulation timeline better suits the patient.

Ellansé vs Radiesse®

Radiesse® (calcium hydroxyapatite, CaHA) offers immediate correction and collagen induction comparable in principle to Ellansé, but comes in a single-duration formulation. For practitioners who buy Radiesse® alongside Ellansé, the most practical clinical difference is duration flexibility — Ellansé’s S/M/L/E range allows longevity to be matched to patient anatomy and maintenance preference in a way a single-duration product does not permit [1].

Ellansé vs JUVÉDERM® and RESTYLANE®

JUVÉDERM® is a hyaluronic acid filler offering volumisation and reversibility with hyaluronidase, but without collagen-stimulating properties. Ellansé delivers both immediate correction and long-term structural improvement through PCL-driven neocollagenesis — a mechanism HA fillers do not replicate [1][2]. Practitioners carrying both can buy JUVÉDERM® at Medica Depot, giving patients the choice between a hyaluronidase-reversible option and a collagen-stimulating approach.

Meanwhile, RESTYLANE® is a hyaluronic acid volumiser with a well-established safety profile and reversibility via hyaluronidase, but without collagen-stimulating properties. The clinical distinction from Ellansé is the same as with other HA fillers: static volumisation versus progressive biostimulation-driven structural improvement [1][2]. Clinics that buy RESTYLANE® at Medica Depot alongside Ellansé can offer patients both mechanisms within a single injectable menu.

Ellansé vs BELOTERO®

BELOTERO® uses cohesive polydensity matrix technology for flexible placement across injection planes and is reversible with hyaluronidase — but like all HA fillers, it does not stimulate collagen production. Practitioners looking to buy BELOTERO® through Medica Depot alongside Ellansé have both a versatile HA option and a PCL biostimulation pathway available for different patient presentations and treatment goals [1][2].

Ellansé Safety Profile — Adverse Events and Contraindications

Common injection-site reactions following Ellansé treatment include swelling, bruising, localized redness, and mild tenderness; these are transient and consistent with those associated with other injectable aesthetic procedures [4][5]. Nodule formation — firm, palpable deposits in the treated area — is a rare adverse event that is technique-dependent and primarily associated with placement outside the recommended injection plane or excessive volume in confined anatomical spaces [1][4]. Technique and injection depth are critical to minimizing this risk [1]. Intravascular injection is a serious complication; careful technique and thorough anatomical knowledge are essential safeguards [4][5].

Contraindications include documented hypersensitivity to PCL or CMC, active bacterial, fungal, or viral skin infection at the injection site, and pregnancy or lactation [4]. The product should not be used in patients with severe immunosuppression that impairs normal inflammatory response [4]. A clinically important patient counseling point: because Ellansé is not a hyaluronic acid filler, hyaluronidase does not dissolve it — unlike HA-based dermal fillers where enzymatic dissolution is an option [4][5]. Pre-treatment informed consent should address irreversibility explicitly and be documented before injection [4].

Order Ellansé at Medica Depot and access competitive wholesale pricing with group buy options for licensed practitioners and clinic teams. Medica Depot provides verified LOT numbers, original manufacturer packaging, and fast shipping to support clinic inventory. Purchase Ellansé — including Ellansé-S, Ellansé-M, Ellansé-L, and Ellansé-E — or contact our representatives for volume discount arrangements. Buy Ellansé wholesale, add to cart, or browse the full range when you buy dermal fillers at Medica Depot today.

Frequently Asked Questions

What is Ellansé?

Ellansé is a CE-marked collagen-stimulating filler by Sinclair Pharma, combining immediate volumisation via CMC carrier with progressive collagen induction via PCL microspheres [1][4]. Available in four duration variants (S/M/L/E) for facial aesthetic indications requiring volume restoration and structural support.

What is Ellansé made of?

Polycaprolactone (PCL) microspheres in a carboxymethylcellulose (CMC) carrier gel [1][2][4]. The product contains no hyaluronic acid, animal collagen, or silicone.

How long does Ellansé last?

Duration is variant-dependent: Ellansé-S approximately one year, Ellansé-M approximately two years, Ellansé-L approximately three years, Ellansé-E approximately four years [1]. Collagen formation continues to develop after CMC resorption, contributing to sustained results throughout the product’s duration [2][3].

Can Ellansé be dissolved?

No. Because Ellansé is not a hyaluronic acid filler, hyaluronidase does not dissolve it [4][5]. Irreversibility must be discussed with patients and documented in informed consent before treatment.

Does Ellansé migrate?

Technique and injection depth are critical to minimizing migration and nodule risk [1]. Placement in the recommended injection plane per the product IFU reduces this risk; placement outside the recommended depth increases it [1][4].

Is Ellansé FDA approved?

No. Ellansé is CE-marked in the EU and distributed in multiple international markets, but is not FDA-approved or cleared for the US [4][5].

Is Ellansé available in the US?

No. Ellansé is not marketed as an FDA-approved dermal filler in the US [5].

Ellansé vs Sculptra® — key difference?

Ellansé provides immediate CMC-based correction alongside PCL-driven collagen stimulation, with visible results from the day of treatment. Sculptra® (PLLA) works gradually with no immediate volumisation — results develop over two to three months [1][2].

What are the side effects of Ellansé filler?

Common transient reactions include injection-site swelling, bruising, and redness [4][5]. Rare adverse events include nodule formation, which is technique-dependent and related to injection depth [1][4]. Because Ellansé is not a hyaluronic acid filler, hyaluronidase does not dissolve it — making careful patient selection and documented informed consent essential [4][5].

Is Ellansé a collagen stimulator or a filler

Both. Ellansé functions as an immediate dermal filler via its CMC carrier and as a collagen biostimulator via its PCL microspheres — commonly categorized as a collagen-stimulating filler [1][2].

Where to order Ellansé wholesale?

Medica Depot offers licensed aesthetic practitioners direct wholesale access to the Ellansé range, with competitive pricing, verified LOT numbers, group buy options, and fast shipping. Buy Ellansé online or add to cart today.

Disclaimer

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations and Resources

1. Melo AR, Nicolau PJ, et al. Recommendations for volume augmentation and rejuvenation of the face and hands with the new generation polycaprolactone-based collagen stimulator (Ellansé®). PMC. 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5685142/
2. Christen M-O, Vercesi F. Polycaprolactone: How a Well-Known and Futuristic Polymer Has Become an Innovative Collagen-Stimulator in Esthetics. Clinical, Cosmetic and Investigational Dermatology. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7065466/
3. Moers-Carpi MM, Sherwood S. Polycaprolactone for the Correction of Nasolabial Folds: A 24-Month Prospective, Randomized Study. PMC. 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC3615178/
4. Ellansé Summary of Safety and Clinical Performance. Sinclair Pharma. 2022. https://sinclair.com/media/dzunuwow/e-mdd-sscp-02-ellanse-mdd-sscp_digital-version-copy.pdf
5. S. Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers). FDA. 2023. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/dermal-fillers-soft-tissue-fillers